DOCSLIB.ORG

Immuno 2010 No. 4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immuno 2010 No. 4 Immunohematology Journal of Blood Group Serology and Education Volume 26, Number 4, 2010 Immunohematology Journal of Blood Group Serology and Education Volume 26, Number 4, 2010 Contents Review 133 Polylactosamines, there’s more than meets the “Ii”: a review of the I system L. Cooling Original Report 156 Attempts to support an immune etiology in 800 patients with direct antiglobulin test–negative hemolytic anemia R.M. Leger, A. Co, P. Hunt, and G. Garratty Review 161 The pathophysiology and prevention of transfusion-related acute lung injury (TRALI): a review D.C. Mair and T. Eastlund Original Report 174 Comparison of gel test and conventional tube test for antibody detection and titration in D-negative pregnant women: study from a tertiary care hospital in North India M.K. Thakur, N. Marwaha, P. Kumar, S.C. Saha, B. Thakral, R.R. Sharma, K. Saluja, H.K. Dhawan, and A. Jain Review 178 The Rh and RhAG blood group systems S.T. Chou and C.M. Westhoff Communication 187 Letter to the editors Anti-Vel and cold-reactive autoantibody Communication 188 Letter from the editors Thank you to the contributors of the 2010 issues 189 Index — Volume 26, Nos. 1, 2, 3, 4, 2010 193 Announcements 195 Advertisements 199 Instructions For Authors Editor-in-Chief Editorial Board Sandra Nance, MS, MT(ASCP)SBB Philadelphia, Pennsylvania Patricia Arndt, MT(ASCP)SBB Paul M. Ness, MD Pomona, California Baltimore, Maryland Managing Editor James P. AuBuchon, MD Joyce Poole, FIBMS Cynthia Flickinger, MT(ASCP)SBB Seattle, Washington Bristol, United Kingdom Philadelphia, Pennsylvania Martha R. Combs, MT(ASCP)SBB Mark Popovsky, MD Durham, North Carolina Braintree, Massachusetts Senior Medical Editor Geralyn M. Meny, MD Geoffrey Daniels, PhD Marion E. Reid, PhD, FIBMS Bristol, United Kingdom New York City, New York Philadelphia, Pennsylvania Anne F. Eder, MD S. Gerald Sandler, MD Technical Editors Washington, District of Columbia Washington, District of Columbia Christine Lomas-Francis, MSc George Garratty, PhD, FRCPath Jill R. Storry, PhD New York City, New York Pomona, California Lund, Sweden Dawn M. Rumsey, ART (CSMLT) Brenda J. Grossman, MD David F. Stroncek, MD Glen Allen, Virginia St. Louis, Missouri Bethesda, Maryland Christine Lomas-Francis, MSc Associate Medical Editors New York City, New York Emeritus Editorial Board Delores Mallory, MT(ASCP) SBB David Moolten, MD Gary Moroff, PhD Supply, North Carolina Philadelphia, Pennsylvania Rockville, Maryland Ralph R. Vassallo, MD John J. Moulds, MT(ASCP)SBB Philadelphia, Pennsylvania Shreveport, Louisiana Editorial Assistant Immunohematology is published quarterly (March, June, September, and December) by the Sheetal Patel American Red Cross, National Headquarters, Washington, DC 20006. Immunohematology is indexed and included in Index Medicus and MEDLINE on the MEDLARS Copy Editor system. The contents are also cited in the EBASE/Excerpta Medica and Elsevier BIOBASE/Current Mary L. Tod Awareness in Biological Sciences (CABS) databases. The subscription price is $40.00 (U.S.) and $50.00 (foreign) per year. Proofreader Subscriptions, Change of Address, and Extra Copies: Lucy Oppenheim Immunohematology, P.O. Box 40325 Philadelphia, PA 19106 Production Assistant Marge Manigly Or call (215) 451-4902 Web site: www.redcross.org/immunohematology Electronic Publisher Copyright 2010 by The American National Red Cross Paul Duquette ISSN 0894-203X On Our Cover “Les yeux clos” (1889–1905), Odilon Redon Odilon Redon created several versions of Les yeux clos (Closed Eyes) between 1889 and 1905. The striking radiance of the woman’s face hints at both the mystery and the significance of inner vision. With her eyes shut, she is unable to see the world, but because the eyes are so central to human identity, the world is also unable to truly see her. Is she asleep or dead? What are her dreams, her thoughts? The subject of the painting was Redon’s wife, although he may have also been inspired by a Michelangelo sculpture of a dying Roman slave. The Ii blood group is the subject of a review article in this issue, which provides insight into the clinical and basic science of polylactosamines. ——DAVID MOOLTEN, MD Review Polylactosamines, there’s more than meets the “Ii”: a review of the I system L. Cooling Key Words: polylactosamine, I blood group, cold agglutinins mutations in the I gene, IGnT (GCNT2).7–10 Serologic studies of family members, who presumably are heterozygous, History can have an intermediate I+i+ phenotype with elevated i The unofficial birth of the I blood group system can and weakened I expression relative to normal controls.2,11 1 be traced to a seminal case report in 1956. Wiener and In certain kindreds, iadult is associated with congenital colleagues at New York University and Jewish Hospital cataracts.12–14 Based on older serologic studies, the 1,15 reported a fatal case of cold agglutinin syndrome caused by a incidence of iadult ranges from 1 in 4400 to 1 in 17,000. The potent autoantibody they named “anti-I” for “individuality.” prevalence of mutant IGnT alleles in the general population The patient was a 62-year-old woman with a 5-year history is unknown but is presumably rare. of anemia and episodes of acute life-threatening hemolysis. Increased i expression can be observed with several Although the patient’s serum was compatible with donor inherited and acquired hemolytic disorders as a sign of RBCs at 37°C, she had periodic acute hemolytic transfusion stressed erythropoiesis. Increased i expression is found reactions with “compatible” RBCs, even after warming the on reticulocytes, and also occurs in megaloblastic anemia, blood before transfusion. In an attempt to provide compatible erythroleukemia, thalassemia, paroxysmal nocturnal blood, the patient’s serum was eventually tested against hemoglobinuria, and other hemolytic disorders.16–18 family members, 22,000 blood donors, and an assortment Increased i is also a common finding in hereditary of animals including rabbit, sheep, horse, and cow. A total of erythroblastic multinuclearity with positive acidified five compatible donors were eventually identified, and their serum lysis test (HEMPAS) disease, a rare hematopoietic RBCs were successfully transfused to the patient during the disorder characterized by dyserythropoiesis, altered RBC next 2 years. Because these donors appeared to lack I, their glycosylation, and hemolysis.19 Unlike other hemolytic RBCs were designated i phenotype. In a desperate moment disorders, the increased i observed on HEMPAS RBCs when “compatible” human blood was unavailable, the patient reflects abnormal Golgi trafficking and glycosylation.20,21 was transfused with cow blood, which had demonstrated only weak activity at 4°C. Not surprisingly, the transfusion Biochemistry was aborted within 10 minutes, after the patient developed Ii Structure anxiety, acute dyspnea, and feelings of “impending doom”! I and i are structurally and biosynthetically related The serologic relationship between I and i phenotypes oligosaccharide chains, composed of repeating units was solidified with the identification of an anti-i by Dr. of N-acetyllactosamine (Fig. 1; [Galβ14GlcNAcβ1-] , Lawrence Marsh.2 The antibody was strongly reactive with n LacNAc). I and i are ubiquitously expressed on human cord RBCs and i RBCs but not normal adult RBCs. More adult tissues and membrane structures. On RBC glycoproteins, importantly, Marsh was able to demonstrate a progressive polylactosamines are expressed as asparagine- or N-linked age-dependent decrease in i on infant RBCs, suggesting a glycans, ranging from biantennary to large, polyvalent developmental relationship between I and i. tetraantennary structures (Fig. 1B). On gut, leukocytes, Ii System and other tissues, polylactosamine may also be expressed As noted by Marsh, I and i are developmentally regulated as O-linked glycans via covalent linkages on serine and antigens on RBCs. At birth, cord RBCs serologically type as threonine residues (Fig. 1C). Polylactosamines are also I–i+. A discernible increase in I expression is observed by 3 found on membrane glycosphingolipids (Fig. 1A), including months, accompanied by parallel decreases in i expression, massive polyglycosylceramides ranging from 20 to 50 with an adult-type I+ phenotype observed by 18 months.2 carbohydrate residues in size.22 Increases in I mirror increases in ABO expression, which Structurally, i is defined as a linear, unbranched type typically reach adult levels by 2 to 3 years of age (see section 2 chain structure bearing at least two successive LacNAc on HDFN).3 Using human anti-I sera, the number of available residues (Fig. 1A).23 I is a branched polylactosamine derived I sites is estimated to be anywhere from 30,000 to 140,000 from i by the addition of a β1,6-linked polylactosamine side on untreated adult RBCs,4–6 but increases nearly threefold chain.23 Antibodies against I, therefore, must recognize after enzyme treatment (see section on Ii antibodies).6 GlcNAcβ16Galβ-R as part of the immune epitope.23,24 The iadult phenotype is a rare, autosomal-recessive trait Although I is often depicted with binary, terminal β13 and characterized by an absence of I on RBCs as a result of β16 LacNAc epitopes, in reality, β1,6 branching can occur IMMUNOHEMATOLOGY, Volume 26, Number 4, 2010 133 L. Cooling Fig. 1 Structures of Ii oligosaccharides on cell membranes. (A) Structure of i-active and I-active glycosphingolipid (N-acetyl ceramide). Endo-ß-endoceramidase can cleave i-active oligosaccharides; however, I-active oligosaccharides are resistant. (B) Structure of biantennary and tetraantennary glycans on N- or asparginine-linked glycoproteins. (C) O-glycan structures. (D) Terminal modification of Ii or type 2 chain oligosaccharides. Cer = ceramide; Gal = galactose; GalNAc = N-acetylgalactosamine; Glc = glucose; GlcNAc = N-acetylglucosamine; Man = mannose. anywhere along the polylactosamine backbone, assuming such as ABO, LeX, sLeX, LeY, and sialo-Ii activity (Fig. the presence of at least two successive LacNAc residues (see 1D).27 On human RBCs, more than 95 percent of all ABO later section).
Load more

Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • "Epitope Mapping: B-Cell Epitopes". In: Encyclopedia of Life Sciences
    Epitope Mapping: B-cell Advanced article Epitopes Article Contents . Introduction GE Morris, Wolfson Centre for Inherited Neuromuscular Disease RJAH Orthopaedic Hospital, . What Is a B-cell Epitope? . Epitope Mapping Methods Oswestry, UK and Keele University, Keele, Staffordshire, UK . Applications Immunoglobulin molecules are folded to present a surface structure complementary to doi: 10.1002/9780470015902.a0002624.pub2 a surface feature on the antigen – the epitope is this feature of the antigen. Epitope mapping is the process of locating the antibody-binding site on the antigen, although the term is also applied more broadly to receptor–ligand interactions unrelated to the immune system. Introduction formed of highly convoluted peptide chains, so that resi- dues that lie close together on the protein surface are often Immunoglobulin molecules are folded in a way that as- far apart in the amino acid sequence (Barlow et al., 1986). sembles sequences from the variable regions of both the Consequently, most epitopes on native, globular proteins heavy and light chains into a surface feature (comprised of are conformation-dependent and they disappear if the up to six complementarity-determining regions (CDRs)) protein is denatured or fragmented. Sometimes, by acci- that is complementary in shape to a surface structure on the dent or design, antibodies are produced against linear antigen. These two surface features, the ‘paratope’ on the (sequential) epitopes that survive denaturation, though antibody and the ‘epitope’ on the antigen, may have a cer- such antibodies usually fail to recognize the native protein. tain amount of flexibility to allow an ‘induced fit’ between The simplest way to find out whether an epitope is confor- them.
    [Show full text]
  • Transfusion Problems in Hemolytic Anemias*
    Transfusion Problems in Hemolytic Anemias* ALI A. HOSSAIN! Department of Pathdlogy, Medical College of Virginia, Richmond 23219 All hemolytic anemias feature shortened red cell Extrinsic Mechanisms survival due to premature hemolysis of the cell. For the Those hemolytic anemias which are due to extrinsic purposes of this presentation, we may classify the factors may be classified, further, as non-immune or hemolytic anemias, most broadly, according to the immune. Non-immune mechanisms include a) drugs mechanisms leading to hemolysis. and chemicals (phenylhydrazine, naphthalene, lead, snake venoms); b) physical agents (heat); c) bacteria Intrinsic Mechanisms and parasites (hemolytic streptococci, Clostridium Hemolytic anemias due to intrinsically defective welchii, Bartonella, plasmodia); and d) acquired sen­ erythrocytes are essentially of three types. First are sitivity to penicillin, methylodopa, Keftin®, or fava those anemias in which the red cells are defective due plant as examples. Some of the agents in this. last to lack of an essential factor, eg, pernicious anemia group serve to lyse the cells, either through duect in relapse. The second type includes those in which action or by formation of antibodies. the red cells have an abnormal shape because of an These hemolytic anemias due to extrinsic factors inherited error in the chemical makeup of the hemo­ of the non-immune variety present no transfusion globin molecules; eg, sickle cells, elliptocytes, sphero­ problem for the Blood Bank. However, it ~~st b.e cytes, and the target
    [Show full text]
  • Hemolytic Disease of the Newborn
    Intensive Care Nursery House Staff Manual Hemolytic Disease of the Newborn INTRODUCTION and DEFINITION: Hemolytic Disease of the Newborn (HDN), also known as erythroblastosis fetalis, isoimmunization, or blood group incompatibility, occurs when fetal red blood cells (RBCs), which possess an antigen that the mother lacks, cross the placenta into the maternal circulation, where they stimulate antibody production. The antibodies return to the fetal circulation and result in RBC destruction. DIFFERENTIAL DIAGNOSIS of hemolytic anemia in a newborn infant: -Isoimmunization -RBC enzyme disorders (e.g., G6PD, pyruvate kinase deficiency) -Hemoglobin synthesis disorders (e.g., alpha-thalassemias) -RBC membrane abnormalities (e.g., hereditary spherocytosis, elliptocytosis) -Hemangiomas (Kasabach Merritt syndrome) -Acquired conditions, such as sepsis, infections with TORCH or Parvovirus B19 (anemia due to RBC aplasia) and hemolysis secondary to drugs. ISOIMMUNIZATION A. Rh disease (Rh = Rhesus factor) (1) Genetics: Rh positive (+) denotes presence of D antigen. The number of antigenic sites on RBCs varies with genotype. Prevalence of genotype varies with the population. Rh negative (d/d) individuals comprise 15% of Caucasians, 5.5% of African Americans, and <1% of Asians. A sensitized Rh negative mother produces anti-Rh IgG antibodies that cross the placenta. Risk factors for antibody production include 2nd (or later) pregnancies*, maternal toxemia, paternal zygosity (D/D rather than D/d), feto-maternal compatibility in ABO system and antigen load. (2) Clinical presentation of HDN varies from mild jaundice and anemia to hydrops fetalis (with ascites, pleural and pericardial effusions). Because the placenta clears bilirubin, the chief risk to the fetus is anemia. Extramedullary hematopoiesis (due to anemia) results in hepatosplenomegaly.
    [Show full text]
  • A Newly Recognized Blood Group in Domestic Shorthair Cats: the Mik Red Cell Antigen
    J Vet Intern Med 2007;21:287–292 A Newly Recognized Blood Group in Domestic Shorthair Cats: The Mik Red Cell Antigen Nicole M. Weinstein, Marie-Claude Blais, Kimberly Harris, Donna A. Oakley, Lillian R. Aronson, and Urs Giger Background: Naturally occurring alloantibodies produced against A and B red cell antigens in cats can cause acute hemolytic transfusion reactions. Blood incompatibilities, unrelated to the AB blood group system, have also been suspected after blood transfusions through routine crossmatch testing or as a result of hemolytic transfusion reactions. Hypothesis: Incompatible crossmatch results among AB compatible cats signify the presence of a naturally occurring alloantibody against a newly identified blood antigen in a group of previously never transfused blood donor cats. The associated alloantibody is clinically important based upon a hemolytic transfusion reaction after inadvertent transfusion of red cells expressing this red cell antigen in a feline renal transplant recipient that lacks this red cell antigen. Methods: Blood donor and nonblood donor cats were evaluated for the presence of auto- and alloantibodies using direct antiglobulin and crossmatch tests, respectively, and were blood typed for AB blood group status. Both standard tube and novel gel column techniques were used. Results: Plasma from 3 of 65 cats and 1 feline renal transplant recipient caused incompatible crossmatch test results with AB compatible erythrocytes indicating these cats formed an alloantibody against a red cell antigen they lack, termed Mik. The 3 donors and the renal transplant recipient were crossmatch-compatible with one another. Tube and gel column crossmatch test results were similar. Conclusions and Clinical Importance: The absence of this novel Mik red cell antigen can be associated with naturally occurring anti-Mik alloantibodies and can elicit an acute hemolytic transfusion reaction after an AB-matched blood transfusion.
    [Show full text]
  • Ige – the Main Player of Food Allergy
    DDMOD-431; No of Pages 8 Vol. xxx, No. xx 2016 Drug Discovery Today: Disease Models Editors-in-Chief Jan Tornell – AstraZeneca, Sweden DRUG DISCOVERY Andrew McCulloch – University of California, SanDiego, USA TODAY DISEASE MODELS IgE – the main player of food allergy 1 2,3 2 Henrike C.H. Broekman , Thomas Eiwegger , Julia Upton , 4, Katrine L. Bøgh * 1 Department of Dermatology/Allergology, University Medical Centre Utrecht (UMCU), Utrecht, The Netherlands 2 Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Paediatrics, Hospital for Sick Children, Toronto, Canada 3 Research Institute, Physiology and Experimental Medicine, The University of Toronto, Toronto, Canada 4 National Food Institute, Technical University of Denmark, Søborg, Denmark Food allergy is a growing problem worldwide, presently Section editor: affecting 2–4% of adults and 5–8% of young children. IgE Michelle Epstein – Medical University of Vienna, is a key player in food allergy. Consequently huge Department of Dermatology, DIAID, Experimental Allergy, Waehringer Guertel 18-20, Room 4P9.02, A1090, efforts have been made to develop tests to detect Vienna, Austria. either the presence of IgE molecules, their allergen binding sites or their functionality, in order to provide allergen ingestion [1], and involve one or more of the follow- information regarding the patient’s food allergy. The ing systems; the skin (pruritus, urticaria, or angioedema), the ultimate goal is to develop tools that are capable of gastro-intestinal tract (diarrhea, vomiting, contractions, in- creased bowel movement), the respiratory tract (asthma at- discriminating between asymptomatic sensitization tack, hoarseness, stridor/laryngeal angioedema) or the and a clinically relevant food allergy, and between cardiovascular system (dizziness, drop in blood pressure, loss different allergic phenotypes in an accurate and trust- of consciousness) [2,3].
    [Show full text]
  • Protein Epitope Mapping by Mass Spectrometry
    Anal. Chem. 1994,66, 3723-3726 Protein Epitope Mapping By Mass Spectrometry Ylngmlng Zhao and Brian T. Chalt’ The Rockefeller University, 1230 York Avenue, New York, New York 10021 A mass spectrometricmethod is described for the rapid mapping antigen bound to an antibody. Alternatively, these workers of linear epitopes in proteins that are bound by monoclonal subjected the peptide to proteolytic digestion and identified antibodies. The method consists of three steps. In the first products that bound to the immobilized antibody. In both step, an antigen protein is digested by a proteolytic enzyme to cases, the peptides of interest were identified by 2Wfplasma produce an appropriate set of peptide fragments. In the second desorption mass spectrometry. step, peptide fragments containing the linear epitope are selected Matrix-assisted laser desorption mass spectrometry (MAL- and separated from the pool of peptide fragments by immu- DI-MS) is a recently developed method for measuring the noprecipitation with the monoclonal antibody. In the final molecular weights of peptides and proteins.12-14 The technique step, the immunoprecipitated peptides are identified by matrix- allows the accurate (better than O.l%), rapid (<1 min), and assisted laser desorption mass spectrometry. The method sensitive (<1 pmol) determination of the molecular weights allows the rapid determination of antigenic sites without tedious of components of complex mixtures of peptides. MALDI- peptide synthesis or protein mutagenesis. The approach is MS is finding wide use for the rapid identification of proteins demonstrated through the mapping of epitopes in two peptides and the elucidation of their primary structures (in particular, (melittin and glucagon-like peptide-1 7-37) against which the definition of posttranslational modifications.) monoclonal antibodies were raised.
    [Show full text]
  • ENCODE DCC Antibody Validation Document
    ENCODE DCC Antibody Validation Document Date of Submission Name: Email: Lab Antibody Name: Target: Company/ Source: Catalog Number, database ID, laboratory Lot Number Antibody Description: Target Description: Species Target Species Host Validation Method #1 Validation Method #2 Purification Polyclonal/ Method Monoclonal Vendor URL: Reference (PI/ Publication Information) Please complete the following for antibodies to histone modifications: if your specifications are not listed in the drop-down box, please write-in the appropriate information Histone Name AA modified AA Position Modification Validation #1 Analysis Insert Validation Image (click here) ARID3A (NB100-279) & (sc-8821) Immunoblot / Immunoprecipitation A. MW (kD) B. MW (kD) C. MW (kD) D. MW (kD) 150 150 150 150 100 100 100 100 75 75 75 75 50 50 50 50 38 38 38 38 25 25 25 20 20 20 25 15 15 15 15 Lane : 1 2 3 4 Lane : 1 2 3 Lane : 1 2 Lane : 1 2 3 A. Western Blot using NB100-279 on nuclear lysates from cell lines GM12878 (Lane1), K562 (Lane2), HeLaS3 (Lane3), and HepG2 (Lane4). B. Immunoprecipitation was performed on nuclear lysates from K562 cells using antibody NB100-279. Lane1: Nuclear lysate. Lane 3: Bound material from control immunoprecipitation with rabbit IgG. Lane 2: Bound material from immunoprecipitation with NB100-279. C. Western Blot using sc-8821 on nuclear lysates from cell lines GM12878 (Lane1), K562 (Lane2). D. Immunoprecipitation was performed on nuclear lysates from K562 cells using antibody sc-8821 and immunoblot with NB100-279. Lane1: Nuclear lysate. Lane 2: Bound material from immunoprecipitation with sc-8821. Lane 3: Bound material from control immunoprecipitation with Goat IgG.
    [Show full text]
  • Flow Reagents Single Color Antibodies CD Chart
    CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n
    [Show full text]
  • Blood Bank I D
    The Osler Institute Blood Bank I D. Joe Chaffin, MD Bonfils Blood Center, Denver, CO The Fun Just Never Ends… A. Blood Bank I • Blood Groups B. Blood Bank II • Blood Donation and Autologous Blood • Pretransfusion Testing C. Blood Bank III • Component Therapy D. Blood Bank IV • Transfusion Complications * Noninfectious (Transfusion Reactions) * Infectious (Transfusion-transmitted Diseases) E. Blood Bank V (not discussed today but available at www.bbguy.org) • Hematopoietic Progenitor Cell Transplantation F. Blood Bank Practical • Management of specific clinical situations • Calculations, Antibody ID and no-pressure sample questions Blood Bank I Blood Groups I. Basic Antigen-Antibody Testing A. Basic Red Cell-Antibody Interactions 1. Agglutination a. Clumping of red cells due to antibody coating b. Main reaction we look for in Blood Banking c. Two stages: 1) Coating of cells (“sensitization”) a) Affected by antibody specificity, electrostatic RBC charge, temperature, amounts of antigen and antibody b) Low Ionic Strength Saline (LISS) decreases repulsive charges between RBCs; tends to enhance cold antibodies and autoantibodies c) Polyethylene glycol (PEG) excludes H2O, tends to enhance warm antibodies and autoantibodies. 2) Formation of bridges a) Lattice structure formed by antibodies and RBCs b) IgG isn’t good at this; one antibody arm must attach to one cell and other arm to the other cell. c) IgM is better because of its pentameric structure. P}Chaffin (12/28/11) Blood Bank I page 1 Pathology Review Course 2. Hemolysis a. Direct lysis of a red cell due to antibody coating b. Uncommon, but equal to agglutination. 1) Requires complement fixation 2) IgM antibodies do this better than IgG.
    [Show full text]
  • Análise Integrativa De Perfis Transcricionais De Pacientes Com
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Ribeirão Preto – 2012 ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Tese apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Genética Orientador: Prof. Dr. Eduardo Antonio Donadi Co-orientador: Prof. Dr. Geraldo A. S. Passos Ribeirão Preto – 2012 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Evangelista, Adriane Feijó Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas. Ribeirão Preto, 2012 192p. Tese de Doutorado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de Concentração: Genética. Orientador: Donadi, Eduardo Antonio Co-orientador: Passos, Geraldo A. 1. Expressão gênica – microarrays 2. Análise bioinformática por module maps 3. Diabetes mellitus tipo 1 4. Diabetes mellitus tipo 2 5. Diabetes mellitus gestacional FOLHA DE APROVAÇÃO ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas.
    [Show full text]
  • Investigation of Four Genes Responsible for Autosomal Recessive Congenital Cataract and Highly Expressed in the Brain in Four Unrelated Tunisian Families
    Open Journal of Ophthalmology, 2012, 2, 64-70 http://dx.doi.org/10.4236/ojoph.2012.23014 Published Online August 2012 (http://www.SciRP.org/journal/ojoph) Investigation of Four Genes Responsible for Autosomal Recessive Congenital Cataract and Highly Expressed in the Brain in Four Unrelated Tunisian Families Manèl Chograni1, Myriam Chaabouni1,2, Faouzi Maazoul2, Habiba Chaabouni Bouhamed1,2* 1Laboratoire de Génétique Humaine, Faculté de Médecine de Tunis, University Tunis Elmanar, Tunis, Tunisia; 2Congenital and Hereditary Disorders Department, Charles Nicolle Hospital, Tunis, Tunisia. Email: *[email protected] Received March 14th, 2012; revised April 28th, 2012; accepted May 11th, 2012 ABSTRACT Purpose: To identify the causative gene for phenotypes associating autosomal recessive congenital cataract, mental re- tardation and congenital cataract, mental retardation and microcephaly in four unrelated Tunisian families. Methods: Four genes (EPHA2, GALK1, GCNT2, and CRYBB1) were selected based on their expression in human brain and their known or putative function. Linkage analysis were performed for the four genes in multiple affected and unaffected families’ members and results were explored by the GeneMapper ID v3.2 software. Results: No linkage was identified for the four studied genes in the four families. Affected members of each family did not share common haplotypes in corresponding candidate regions containing selected gene. Conclusion: Although the four studied genes were reported responsible for autosomal recessive congenital cataract and highly expressed in the human brain, we report no linkage for EPHA2, GALK1, GCNT2, and CRYBB1 genes in four families with congenital cataract, mental retardation and con- genital cataract, mental retardation and microcephaly. Keywords: Congenital Cataract; Mental Retardation; Microcephaly; Autosomal Recessive; Association; Linkage Study 1.
    [Show full text]